Efficacy, Safety and Pharmacokinetic Study of CPL500036 in Patients with Levodopa Induced Dyskinesia

Celon Pharma

Status and phase: Completed; Phase 2

Conditions: Parkinson Disease; Dyskinesia, Medication-Induced

Treatments: Drug: CPL500036 - low dose; Drug: Placebo; Drug: CPL500036 - high dose

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT05297201

03PDE2020

Details and patient eligibility

About

The aim of the study is to determine potential anti-dyskinetic properties of CPL500036 (PDE10A inhibitor) in Parkinson disease patients suffering from levodopa Induced dyskinesia. The study is to determine the efficacy and dose response of two CPL500036 doses, compared with placebo.

Full description

This is a double-blind, randomized, placebo-controlled, parallel-group, dose ranging study, to explore the efficacy, safety, tolerability and pharmacokinetic (PK) of low and high dose of CPL500036 an phosphodiesterase 10A (PDE10A) inhibitor in Parkinson's disease patients with levodopa induced dyskinesia (LID) when administered for 28 days. The study will be conducted at multiple Clinical Sites. Approximately 108 patients will be randomized at 1:1:1 ratio to receive low or high dose of CPL500036 or placebo in a blinded manner, once daily for 28 days (Day 1 to Day 28). The study will comprise of Screening, Baseline (a 4-day in-house period), a Treatment Period and a Follow-Up Period. The patients will be discharged from clinical units during the Treatment Period. Approximately 30% of the patients (11 patients in each of the 3 treatment groups) will undergo extensive PK blood sampling during the Treatment Period and the remaining 70% of the patients will undergo sparse PK blood sampling. Patients from extensive PK blood sampling will be discharged from the Clinical Site on Day 8 and Day 1 for patients from sparse PK blood sampling group respectively.

Enrollment: 105 patients

Sex: All

Ages: 50 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Signed and dated written informed consent.

2. Male or female patient aged between 50 and 80, diagnosed of idiopathic Parkinson's disease according to the United Kingdom Parkinson's Disease Society Brain Bank Clinical Diagnosis Criteria.

3. The patient is on stable dose of Levodopa.

4. Other anti-PD medications are allowed if dosing is optimized and stably used.

5. The patient is has been treated with Levodopa and is suffering from temporally predictable peak-dose LID.

6. Patient declare that dyskinesia is problematic or disabling.

7. Score of dyskinesia is at least 2 on part IV, item 4.2 (of the MDS-UPDRS at Screening and on Day -1).

8. Patient with Hoehn-Yahr stages 2 to 4 (in OFF stage).

9. Female patient is not pregnant (at Screening and Day -1), not breastfeeding and at least 1 of the following conditions applies: (i) woman of non-childbearing potential; (ii) woman of childbearing potential, using contraceptive methods during the Treatment Period and for at least 28 days after the last dose of the study drug.

   The following are acceptable contraceptive methods: bilateral tubal occlusion, male sterilization, established proper use of hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices and copper intrauterine devices, male or female condom with spermicide; and cap, diaphragm or sponge with spermicide.

10. Male patient must agree to use a barrier method of contraceptive for at least 90 days after the last dose of the study drug.

11. Patient agrees to blood sample collection for DNA analysis.

Exclusion criteria

1. The patient has (suspected) atypical Parkinson's disease.
2. The patient has a history of neurosurgical intervention because of Parkinson's disease.
3. Patient has unstable medical status which may impact the ability of the patients to participate or potentially confound the study result.
4. Patient has a history of psychotic event induced by anti-PD treatments or impulse control disorder.
5. The patient has any moderate or severe neuromuscular, locomotor disease, that interfere with the study scoring.
6. The Patient has a history of severe head injury, stroke or any diagnosis of significant nervous system disease.
7. Patient has a history of substance abuse or alcohol abuse within 12 months prior to Screening.
8. The patient is pregnant or lactating or intending to become pregnant or intending to donate ova.
9. Patient has a history of neuroleptic malignant syndrome, or known personality disorder, or other psychiatric disorder that, in the opinion of the Investigator, would interfere with participation in the study.
10. Patient with the presence of cognitive impairment evidenced by a Mini-Mental State Exam (MMSE) of less than 19.
11. Patients is considered by the Investigator to be at imminent risk of suicide or injury to self or others.
12. Patients has any existing or previous history of cancer or has newly diagnosed diabetes.
13. Patient has abnormal ECG that, in the opinion of the Investigator, increases the risks associated with participating in the study.
14. Patient has abnormal QT interval, history of unexplained syncope or known family history of sudden death due to QT abnormality.
15. The patient has any laboratory values outside the normal range that are considered by Investigator to be clinically significant at Screening.
16. Patient participated in another interventional clinical study with an IMP

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Parallel Assignment

Masking: Double Blind

---

105 participants in 3 patient groups, including a placebo group

CPL500036 low dose

Experimental group

Description:

Patients will receive 20 mg of CPL500036 administered once daily for 28-days treatment period.

Treatment:

Drug: CPL500036 - low dose

CPL500036 high dose

Experimental group

Description:

Patients will receive 40 mg of CPL500036 administered once daily for 28-days treatment period.

Treatment:

Drug: CPL500036 - high dose

Placebo

Placebo Comparator group

Description:

Patients will receive placebo administered once daily for 28-days treatment period.

Treatment:

Drug: Placebo